🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Biden pledges faster U.S. approval for cancer drug cocktails

Published 01/19/2016, 01:48 PM
Updated 01/19/2016, 01:51 PM
© Reuters. US Vice President Biden addresses the session "Cancer Moonshot: A Call to Action" during the annual meeting 2016 of the WEF in Davos

By Ben Hirschler

DAVOS, Switzerland (Reuters) - U.S. Vice President Joe Biden said on Tuesday that the United States would speed up the approval of promising new drug combinations in his government's newly announced drive to cure cancer "once and for all".

Biden, who lost his 46-year-old son Beau to brain cancer last year, set out his plans at a World Economic Forum meeting of international cancer experts in Davos, a week after being appointed to lead the initiative by President Barack Obama.

So-called combination therapy is increasingly seen as central to fighting tumours, as scientists unlock the different genetic factors driving cancer cell growth, but bringing such cocktails to market can be a slow and costly.

Biden said he had hosted a meeting at his home with three unnamed large drug companies and the head of the U.S. Food and Drug Administration (FDA) at which both sides had pledged to do more to get novel cancer drug cocktails to patients.

"The head of the FDA made a commitment that everybody would move much more rapidly in approving combinations," Biden said.

At the same, the pharmaceutical industry executives had all said they were "open to different way of doing business" in order to ensure that promising drugs from different companies were tested together as early as possible, he added.

Cancer experts are particularly excited by the promise of new immunotherapy medicines that help the body's immune system fight tumours and which have been shown to work well when used alongside other drugs.

Francis Collins, director of the U.S. National Institutes of Health, described their potential as "breath-taking".

But such immunotherapy drugs are expensive - typically costing well over $100,000 a year per patient - and companies have traditionally been defensive about sharing early-stage medical experiments.

Obama's call to "make America the country that cures cancer once and for all" in the last State of the Union address of his presidency has led to criticism from some scientists of an over-simplified approach to the killer condition.

The latest government-led initiative has echoes of former President Richard Nixon's unsuccessful "War on Cancer" in the 1970s, since when scientists have discovered that cancer is hundreds of different diseases rather than one single disorder, making the notion of a single cure outdated.

Biden acknowledged the complexity in Davos.

© Reuters. US Vice President Biden addresses the session "Cancer Moonshot: A Call to Action" during the annual meeting 2016 of the WEF in Davos

"I'm not naive enough to think or suggest we are going to have a cure for every cancer in the world in the near term," he said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.